Downregulation of mTOR-TF axis activity likely contributes to the therapeutic mechanism of mTORC1/2- and TF-targeted agents in EGFR-mut advanced NSCLC and GBM. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.